CD274 and non-small cell lung carcinoma: Despite higher BMI has been consistently associated with increased risk of treatment-related adverse events in patient receiving checkpoint inhibitors [74,75], in an Italian cohort analysis including 962 metastatic NSCLC patient treated with pembrolizumab and 426 treated with chemotherapy, baseline obesity correlated with significantly improved overall response rate (ORR), PFS and OS in patients with a PD-L1 expression of ≥50%, receiving first line pembrolizumab, but not among patients treated with chemotherapy [76].